Advertisement Banner
  • Home
  • News
    • PRESS RELEASE
  • Shop
  • BUSINESS
    • CRYPTO
    • ECONOMY
    • FINANCE
    • MARKET
    • MONEY
  • TECH
    • APPS
    • GADGET
    • MOBILE
    • SCIENCE
  • SOCIAL MEDIA
  • ENTERTAINMENT
    • ARTS & THEATER
    • GAMING
    • GAMBLING
    • MOVIE
    • MUSIC
    • SHOWS
    • SPORTS
  • LIFESTYLE
    • CELEBRITY
    • CULTURE
    • Education
    • FASHION
    • FOOD
    • HEALTH
    • HISTORY
    • Nature
    • Religion
    • Shopping
    • TRAVEL
  • REAL ESTATE
  • Blog
  • Classifieds
No Result
View All Result

No products in the cart.

  • Home
  • News
    • PRESS RELEASE
  • Shop
  • BUSINESS
    • CRYPTO
    • ECONOMY
    • FINANCE
    • MARKET
    • MONEY
  • TECH
    • APPS
    • GADGET
    • MOBILE
    • SCIENCE
  • SOCIAL MEDIA
  • ENTERTAINMENT
    • ARTS & THEATER
    • GAMING
    • GAMBLING
    • MOVIE
    • MUSIC
    • SHOWS
    • SPORTS
  • LIFESTYLE
    • CELEBRITY
    • CULTURE
    • Education
    • FASHION
    • FOOD
    • HEALTH
    • HISTORY
    • Nature
    • Religion
    • Shopping
    • TRAVEL
  • REAL ESTATE
  • Blog
  • Classifieds
No Result
View All Result
No Result
View All Result
Home PRESS RELEASE

Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe

North Dakota Digital News by North Dakota Digital News
January 22, 2023
in PRESS RELEASE
37 2
0
Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
32
SHARES
356
VIEWS
Share on TwitterShare on Facebook


HYDERABAD, India–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced that it has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, DRL_RI, for filing in highly regulated markets such as the United States, Europe and other regions.

DRL_RI is being developed as a biosimilar of rituximab, a cluster of differentiation 20 (CD20) directed cytolytic antibody for approval in the United States, European Union and other regions for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.

Dr. Reddy’s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets. The company undertook further clinical development to meet regulatory requirements of highly regulated markets. With the successful completion of these clinical studies, Dr. Reddy’s is now preparing to file Biologics License Application (BLA) / Marketing Authorisation Application (MAA) dossiers with various regulatory authorities globally.

Dr. Jayanth Sridhar, Global Head of Biologics at Dr. Reddy’s, said: “This is a very important milestone in our biosimilars journey. The successful completion and positive outcome of these clinical studies highlights our capability for global clinical development of biosimilar products for highly regulated and global markets. These results underscore our commitment to developing high quality biosimilars and reinforce the potential of DRL_RI as a safe and effective treatment option to patients across the globe.”

Dr. Reddy’s is currently collaborating with its partner Fresenius Kabi to commercialise its proposed biosimilar of rituximab in the United States. The company intends to commercialise the product in Europe and other geographies directly.

About Dr. Reddy’s clinical studies for its proposed biosimilar of rituximab, DRL_RI:

  1. RI-01-003: This study demonstrated pharmacokinetic equivalence and similarity in pharmacodynamics, safety and immunogenicity between DRL_RI and EU reference medicinal product* and U.S. reference product**.
  2. RI-01-006 (FLINTER): This study demonstrated efficacy equivalence and similarity in safety and immunogenicity between DRL_RI and EU reference medicinal product* in patients with Low Tumour Burden Follicular Lymphoma
  3. RI-01-007: This study demonstrated similar safety and immunogenicity profile between the DRL_RI, EU reference medicinal product* and U.S. reference product** groups upon single transition from either of them, in subjects with active rheumatoid arthritis.

*EU reference medicinal product is MabThera®

**U.S. reference product is Rituxan®

MabThera® and Rituxan® are registered trademarks of Roche.

About Dr. Reddy’s biosimilars programme:

Dr. Reddy’s biosimilars business is part of our key strategic initiatives expected to drive both near-term and future growth. Over the last 20 years, our Biologics team has developed into a fully integrated organisation with robust capabilities in the development, manufacture and commercialisation of a range of biosimilar products in oncology and immunology. We have a current portfolio of six commercial products marketed in India and over 25 Emerging Markets. In addition, we have several products in the pipeline in oncology and auto-immune diseases in various stages of development for global launches across regulated as well as emerging markets. We recently announced the successful completion of Phase I study and initiation of Phase III study of DRL_TC, our proposed biosimilar of tocilizumab, for global markets. We are also ramping up manufacturing capacity to support our global expansion plans.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the “Risk Factors” and “Forward-Looking Statements” sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.



Source link

Tweet8Share13Share3Share
Previous Post

Kylie Jenner Shares Baby Boy’s Name Aire and First Photos

Next Post

IoT In Education Is Shaping The Future

North Dakota Digital News

North Dakota Digital News

Next Post
IoT In Education Is Shaping The Future

IoT In Education Is Shaping The Future

Discussion about this post

Bismarck
◉
9°
Sunny
8:18 am5:31 pm CST
Feels like: 9°F
Wind: 1mph S
Humidity: 87%
Pressure: 30.01"Hg
UV index: 1
MonTueWed
30/16°F
30/16°F
19/12°F
Weather forecast Bismarck, North Dakota ▸
United States Attorney Announces Extradition Of FTX Founder Samuel Bankman-Fried To The United States And Guilty Pleas Of Former CEO Of Alameda Research And Former Chief Technology Officer Of FTX | USAO-SDNY
PRESS RELEASE

District of Massachusetts | Three Charged in Firearm Straw Purchasing Conspiracy

by North Dakota Digital News
January 22, 2023
Things You Should Never, Ever Do in USA 2023
TRAVEL

Things You Should Never, Ever Do in USA 2023

by North Dakota Digital News
January 22, 2023
Ukraine war exposes Europe’s reliance on Russian rail for China trade
BUSINESS

Ukraine war exposes Europe’s reliance on Russian rail for China trade

by North Dakota Digital News
January 22, 2023
We certainly don’t need a repeat of last year • TechCrunch
TECH

We certainly don’t need a repeat of last year • TechCrunch

by North Dakota Digital News
January 22, 2023
United States Attorney Announces Extradition Of FTX Founder Samuel Bankman-Fried To The United States And Guilty Pleas Of Former CEO Of Alameda Research And Former Chief Technology Officer Of FTX | USAO-SDNY
PRESS RELEASE

Former Contractor Pleads Guilty to Conspiracy to Defraud the United States | OPA

by North Dakota Digital News
January 22, 2023
Kylie Jenner Clarifies How to Pronounce Her Son Aire’s New Name
ENTERTAINMENT

Kylie Jenner Clarifies How to Pronounce Her Son Aire’s New Name

by North Dakota Digital News
January 22, 2023
Hoarder Houses and Investing Tips for Late Starters
REAL ESTATE

Hoarder Houses and Investing Tips for Late Starters

by North Dakota Digital News
January 22, 2023
Cubs Agree to Terms With Shortstop Dansby Swanson on a Seven-year Major League Contract
PRESS RELEASE

Ten umpires promoted to Major League Staff

by North Dakota Digital News
January 22, 2023
Why This Universe? Maybe It’s Not Special—Just Probable
SCIENCE

Why This Universe? Maybe It’s Not Special—Just Probable

by North Dakota Digital News
January 22, 2023
Samsung Galaxy Tab S6 Lite’s Wi-Fi model is receiving Android 13-based One UI 5.0 update
MOBILE

Samsung Galaxy Tab S6 Lite’s Wi-Fi model is receiving Android 13-based One UI 5.0 update

by North Dakota Digital News
January 22, 2023
Microsoft will shut down AltspaceVR on March 10th
GADGET

Microsoft will shut down AltspaceVR on March 10th

by North Dakota Digital News
January 22, 2023
Mark Brooks Internet Dating Business Presentation – Top UK & US Dating Apps, 2019
APPS

Mark Brooks Internet Dating Business Presentation – Top UK & US Dating Apps, 2019

by North Dakota Digital News
January 22, 2023

About Us

North Dakota Digital News

Category

  • APPS
  • ARTS & THEATER
  • BUSINESS
  • CELEBRITY
  • CRYPTO
  • CULTURE
  • ECONOMY
  • Education
  • ENTERTAINMENT
  • FASHION
  • FINANCE
  • FOOD
  • GADGET
  • Gambling
  • GAMING
  • HEALTH
  • HISTORY
  • LIFESTYLE
  • MARKET
  • MOBILE
  • MONEY
  • MOVIE
  • MUSIC
  • Nature
  • News
  • PRESS RELEASE
  • REAL ESTATE
  • Religion
  • SCIENCE
  • Shopping
  • SHOWS
  • SPORTS
  • TECH
  • TRAVEL
PRESS RELEASE

District of Massachusetts | Three Charged in Firearm Straw Purchasing Conspiracy

January 22, 2023
TRAVEL

Things You Should Never, Ever Do in USA 2023

January 22, 2023
BUSINESS

Ukraine war exposes Europe’s reliance on Russian rail for China trade

January 22, 2023

© 2022 northdakotadigitalnews.com

No Result
View All Result
  • Home
  • News
    • PRESS RELEASE
  • Shop
  • BUSINESS
    • CRYPTO
    • ECONOMY
    • FINANCE
    • MARKET
    • MONEY
  • TECH
    • APPS
    • GADGET
    • MOBILE
    • SCIENCE
  • SOCIAL MEDIA
  • ENTERTAINMENT
    • ARTS & THEATER
    • GAMING
    • GAMBLING
    • MOVIE
    • MUSIC
    • SHOWS
    • SPORTS
  • LIFESTYLE
    • CELEBRITY
    • CULTURE
    • Education
    • FASHION
    • FOOD
    • HEALTH
    • HISTORY
    • Nature
    • Religion
    • Shopping
    • TRAVEL
  • REAL ESTATE
  • Blog
  • Classifieds

© 2022 northdakotadigitalnews.com

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In